Paper: Patient-Reported-Outcomes and Safety of Autologous Stem Cell Transplantation in Multiple Sclerosis: A Single Center Experience with the “Mexican Method” in 1300 Persons

Oral and Poster Abstracts Oral 731. Autologous Transplantation: Clinical and Epidemiological: Lymphoma, AML, and Multiple Sclerosis Research, Biological therapies, autoimmune disorders, epidemiology, Clinical Research, health outcomes research, patient-reported outcomes, Diseases, Immune Disorders, Therapies, Transplantation Juan Carlos Olivares-Gazca,…

Read the full article here

Source: ash.confex.com

Categories: Hem/Oncs, Latest Headlines

Tags: ASH22, MultipleSclerosis

Tweets with this article

Nico Gagelmann

#MultipleSclerosis at #ASH22: -ASCT for MS is a game-changer -people from Europe travel to 🇲🇽 to get it, why? -bc many insurances dont cover it -Cyclophosphamide 200 mg/kg + rituximab 1g -n=1300 (!) -at 2 years: response ~80%, patient-reported outcomes!https://t.co/4CwYPtpAwa /3 https://t.co/AAWQQsBEN6

Paper: Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant

Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma: Clinic al and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Clinical Practice (Health Services…

Al-Ola A Abdallah MD April 18, 2024

Webprogram Unavailable

Please click HERE if you are not redirected in 5

Mike Thompson, MD, PhD, FASCO April 18, 2024

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant…

Mike Thompson, MD, PhD, FASCO April 12, 2024